<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031651</url>
  </required_header>
  <id_info>
    <org_study_id>PUDILAN</org_study_id>
    <nct_id>NCT04031651</nct_id>
  </id_info>
  <brief_title>Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World</brief_title>
  <official_title>Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain the characteristics of adverse reactions/incidents, analyze the influencing factors
      and calculate the incidence of adverse reactions/incidents monitored by Pudilan Xiaoyan Oral
      Liquid in key specialties in the real world, so as to provide a basis for clinical safe and
      rational drug use.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reaction</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of Reduning Injection'Adverse Drug Reaction（ADRs）and Identify Factors That Contributed to the Occurrence of the Adverse Drug Reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Ratio of Body Temperature to Normal</measure>
    <time_frame>7 days</time_frame>
    <description>The Ratio of Body Temperature to Normal(Lower Than 37.3ºC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver function</measure>
    <time_frame>7 days</time_frame>
    <description>Observation of liver function in at least 3000 patients before and after medication.The liver function includes glutamic-pyruvic transaminase,glutamic-oxalacetic transaminase.To observe whether the above liver function indexes appear abnormal once after medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of renal function</measure>
    <time_frame>7 days</time_frame>
    <description>Observation of renal function in at least 3000 patients before and after medication.The renal function includes creatinine,usea nitrogen.To observe whether the above renal function indexes appear abnormal once after medication.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Respiratory Infectious Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pudilan Xiaoyan Oral Liquid</intervention_name>
    <description>In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        To obtain the characteristics of adverse reactions/incidents, analyze the influencing
        factors and calculate the incidence of adverse reactions/incidents monitored by Pudilan
        Xiaoyan Oral Liquid in key specialties in the real world, so as to provide a basis for
        clinical safe and rational drug use.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1)Upper respiratory tract infection patients using Pudilan antiphlogistic oral liquid
             ;

          -  (2)Aged between 18 and 80.

        Exclusion Criteria:

          -  Lactating women, pregnant women, pregnant planners, psychiatric patients, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanming Xie, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanming Xie, BA</last_name>
    <phone>86-13911112416</phone>
    <email>datamining5288@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Miao, doctor</last_name>
    <phone>86-13910812309</phone>
    <email>wlxing@126.com</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yanming Xie</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <keyword>Pudilan Xiaoyan Oral Liquid</keyword>
  <keyword>Safety monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

